|Mr. Mitchell Rubenstein||Co-Founder & Director||665.2k||N/A||1954|
|Mr. David Collins||Investor Relations Firm, Catalyst IR||N/A||N/A||N/A|
NovelStem International Corp. focuses on developing and commercialization of diagnostic technology that can predict patients' resistance to chemotherapy allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. It has a collaboration agreement with NewStem Ltd. for stem-cell technology platform in cancer immunotherapy and COVID-19 resistance. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018 as a result of its business focus shift from advertising services to stem cell-based diagnostics for cancer chemotherapies. The company was founded in 1993 and is headquartered in Boca Raton, Florida.
NovelStem International Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.